Varchetta et al. analysed circulating mononuclear cells in 18 breast cancer patients after treatment of Her2 targeted-trastuzumab therapy and found that NK cells and CD56+ T cells were involved in trastuzumab treatment and concluded "quantity and lytic efficiency of CD16+ lymphocytes [i.e., NK cells] are major factors for ADCC induction by trastuzumab" [50]. This evidence concerns the gene NCAM1 and breast carcinoma.